At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 151 enrolled
Drug / intervention
225 mg BNC210 +2 moredrug
Likely dose
225 mg BNC210from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of BNC210 Compared to Placebo for the Acute Treatment of Social Anxiety Disorder
In Brief
A Phase 2 clinical trial evaluating 225 mg BNC210, 675 mg BNC210, and 1 other intervention for Social Anxiety Disorder. Completed, enrolled 151 participants across 15 sites.
Detailed Summary
The purpose of this study is to assess the effects of an acute dose of BNC210 compared to placebo on reducing anxiety provoked by a speaking challenge and measured using the Subjective Units of Distress Scale (SUDS) in patients with Social Anxiety Disorder (SAD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSocial Anxiety Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedJan 2022
Enrollment StartFeb 2022
Primary CompletionOct 2022
Study CompletionOct 2022
TodayJul 2026
First PostedJan 14, 2022
Enrollment StartFeb 2, 2022
Primary CompletionOct 10, 2022
Study CompletionOct 17, 2022
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 4.5 years ago
Interventions
225 mg BNC210drug
225 mg BNC210
675 mg BNC210drug
675 mg BNC210
Placebodrug
Placebo